Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis

Journal of Chemotherapy

Volumn 20, Issue 2, 2008, Pages 166-169

  Taccetti, Giovanni ^a   Campana, S ^a   Neri, A S ^a   Boni, V ^c   Festini, F ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c NONE

Author keywords

Antibiotic treatment; Cystic fibrosis; Early eradication treatment; P. aeruginosa

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; MACROLIDE; MEROPENEM; PIPERACILLIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; LUNG FIBROSIS; MAINTENANCE THERAPY; MONOTHERAPY; NEPHROTOXICITY; OTOTOXICITY; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; TREATMENT RESPONSE;

EID: 44849133936     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.2.166     Document Type: Short Survey

References (21)

1. Gibson R, Burns J, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168 (8):918-951.
2. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361 (9358):681-689.
3. Bauernfeind A, Przyklenk B. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis. Behring Inst Mitt. 1997; 98:256-261.
4. Cystic Fibrosis Foundation, Patient Registry 2005 Annual Report, Bethesda, Maryland
5. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23 (5): 330-335.
6. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication Therapy against P. aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26 (3): 1-4.
7. Hoiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J Cyst Fibros 2002; 1 (4): 249-254.
8. Govan JRW. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 2002; 1 (Suppl): S203-S208.
9. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006 ;(1): CD004197.
10. Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa infection in people with cystic fibrosis: suggestion for prevention and infection control. Cystic Fibrosis Trust 2001. Bromley
11. Doring G, Hoiby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European Consensus. J Cyst Fibros 2004; 3 (2): 67-91.
12. Hoiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2000;2 (6):451-463.
13. Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57 (2):306-311.
14. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139 (3):359-365.
15. Smyth A, Tan K, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D Knox A for the TOPIC Study Group. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005; 365 (9459): 573-578.
16. Elborn JS, Prescott RJ, Stack BHR, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55 (5): 355-358.
17. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290 (13) :1749-1756.
18. Ramsey BW, Pepe MS, Quan J et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340 (1):23-30.
19. Conway SP. Evidence for using nebulised antibiotics in cystic fibrosis. Arch Dis Child 1999; 80 (4): 307-309.
20. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20 (3):658-664.
21. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001;7 (6):434-440.